CymaBay Therapeutics Past Earnings Performance
Past criteria checks 0/6
CymaBay Therapeutics's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 98.2% per year.
Key information
-5.3%
Earnings growth rate
4.9%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 98.2% |
Return on equity | -36.1% |
Net Margin | -339.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%
Feb 15Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher
Dec 22CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?
Dec 28CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01
Aug 11Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Jul 13CymaBay: Long-Term Potential Based On Prior PBC Trial Results
Jun 27Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?
Mar 17Why I've Taken A 'Starter' Position In CymaBay Therapeutics
Jan 20Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Dec 03We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
May 15We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely
Jan 29CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
Nov 17CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
Nov 08CymaBay Therapeutics EPS in-line
Nov 05Revenue & Expenses BreakdownBeta
How CymaBay Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 31 | -105 | 52 | 0 |
30 Sep 23 | 31 | -90 | 39 | 26 |
30 Jun 23 | 31 | -81 | 33 | 26 |
31 Mar 23 | 0 | -107 | 27 | 26 |
31 Dec 22 | 0 | -106 | 25 | 0 |
30 Sep 22 | 0 | -106 | 24 | 21 |
30 Jun 22 | 0 | -104 | 23 | 21 |
31 Mar 22 | 0 | -100 | 24 | 21 |
31 Dec 21 | 0 | -90 | 23 | 0 |
30 Sep 21 | 0 | -79 | 22 | 4 |
30 Jun 21 | 0 | -68 | 21 | 8 |
31 Mar 21 | 0 | -55 | 18 | 11 |
31 Dec 20 | 0 | -51 | 17 | 13 |
30 Sep 20 | 0 | -65 | 16 | 13 |
30 Jun 20 | 0 | -80 | 17 | 15 |
31 Mar 20 | 0 | -93 | 18 | 17 |
31 Dec 19 | 0 | -103 | 19 | 19 |
30 Sep 19 | 0 | -93 | 19 | 20 |
30 Jun 19 | 0 | -85 | 18 | 17 |
31 Mar 19 | 0 | -79 | 17 | 16 |
31 Dec 18 | 0 | -73 | 14 | 14 |
30 Sep 18 | 5 | -58 | 13 | 12 |
30 Jun 18 | 5 | -48 | 12 | 10 |
31 Mar 18 | 5 | -39 | 12 | 8 |
31 Dec 17 | 10 | -28 | 12 | 7 |
30 Sep 17 | 5 | -29 | 12 | 6 |
30 Jun 17 | 5 | -27 | 12 | 6 |
31 Mar 17 | 5 | -25 | 11 | 6 |
31 Dec 16 | 0 | -27 | 10 | 6 |
30 Sep 16 | 0 | -26 | 9 | 6 |
30 Jun 16 | 0 | -26 | 9 | 6 |
31 Mar 16 | 0 | -20 | 9 | 6 |
31 Dec 15 | 0 | -16 | 9 | 5 |
30 Sep 15 | 0 | -22 | 9 | 6 |
30 Jun 15 | 0 | -22 | 9 | 7 |
31 Mar 15 | 0 | -24 | 8 | 4 |
31 Dec 14 | 0 | -32 | 8 | 4 |
30 Sep 14 | 0 | 208 | 8 | 4 |
30 Jun 14 | 0 | 257 | 7 | 2 |
31 Mar 14 | 0 | 240 | 6 | 3 |
31 Dec 13 | 0 | 244 | 5 | 3 |
30 Sep 13 | 0 | 11 | 4 | 4 |
30 Jun 13 | 3 | -36 | 4 | 4 |
31 Mar 13 | 3 | -23 | 4 | 5 |
Quality Earnings: CBAY is currently unprofitable.
Growing Profit Margin: CBAY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CBAY is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare CBAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: CBAY has a negative Return on Equity (-36.05%), as it is currently unprofitable.